Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155401 | 0.81 | L3MBTL1 (0.42) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL13693180 | 0.79 | L3MBTL1 (0.38) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL10282182 | 0.79 | NUDT1 (0.41) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL19865160 | 0.77 | L3MBTL1 (0.53) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL24529479 | 0.76 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL103894 | 0.76 | HTR2C (0.53) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL104697 | 0.76 | L3MBTL1 (0.35) | L3MBTL1NUDT1 | |
| SCHEMBL8240995 | 0.76 | L3MBTL1 (0.35) | L3MBTL1NUDT1 | |
| SCHEMBL103804 | 0.75 | NUDT1 (0.46) | L3MBTL1NUDT1TNKS | |
| SCHEMBL14507510 | 0.74 | PTGS1 (0.40) | L3MBTL1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9284317-B2 | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9284317-B2 | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| WO-2008057512-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058873-A2 | IMIDAZOPYRAZINES AS CYCLIN DEPENTEND KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | HTR2C 2459/4885L3MBTL1 3942/4885TTK 106/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | HTR2C 3236/4885L3MBTL1 2624/4885TTK 45/4885 |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HTR2C 125/4885L3MBTL1 4652/4885TTK 4033/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | HTR2C 3073/4885L3MBTL1 985/4885TTK 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.